{
    "organizations": [],
    "uuid": "549489a4aec1cad7b87d6add1bee73aa63c80c74",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-inventiva-fy-operating-loss-widens/brief-inventiva-fy-operating-loss-widens-to-20-9-million-euros-idUSFWN1QP0T0",
    "ord_in_thread": 0,
    "title": "BRIEF-Inventiva FY Operating Loss Widens to 20.9 Million Euros",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 7 (Reuters) - Inventiva Sa:\n* FY OPERATING LOSS EUR 20.9 MILLION VERSUS EUR 13.0 MILLION YEAR AGO‍​\n* FY REVENUE EUR 6.5 MILLION VERSUS EUR 9.4 MILLION YEAR AGO‍​\n* CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL INSTRUMENTS AMOUNTED TO €59 MILLION AT DECEMBER 31, 2017\n* FY NET LOSS EUR 17.2 MILLION VERSUS EUR 7.0 MILLION YEAR AGO‍​\n* ‍CLINICAL DEVELOPMENT OF NEW DRUG CANDIDATE, ABBV-157, IS EXPECTED TO BEGIN IN 2018​\n* PARTNERSHIP WITH ABBVIE AND BOEHRINGER INGELHEIM IS ADVANCING ON SCHEDULE\n* ‍TOPLINE RESULTS OF PHASE IIB FASST TRIAL ARE EXPECTED ON SCHEDULE AT BEGINNING OF 2019​\n* CLINICAL DEVELOPMENT OF NEW DRUG CANDIDATE, ABBV-157, EXPECTED TO BEGIN IN 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-08T01:20:00.000+02:00",
    "crawled": "2018-03-08T17:33:46.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "inventiva",
        "sa",
        "fy",
        "operating",
        "loss",
        "eur",
        "million",
        "versus",
        "eur",
        "million",
        "year",
        "fy",
        "revenue",
        "eur",
        "million",
        "versus",
        "eur",
        "million",
        "year",
        "cash",
        "cash",
        "equivalent",
        "current",
        "financial",
        "instrument",
        "amounted",
        "million",
        "december",
        "fy",
        "net",
        "loss",
        "eur",
        "million",
        "versus",
        "eur",
        "million",
        "year",
        "development",
        "new",
        "drug",
        "candidate",
        "expected",
        "begin",
        "partnership",
        "abbvie",
        "boehringer",
        "ingelheim",
        "advancing",
        "schedule",
        "result",
        "phase",
        "iib",
        "fasst",
        "trial",
        "expected",
        "schedule",
        "beginning",
        "clinical",
        "development",
        "new",
        "drug",
        "candidate",
        "expected",
        "begin",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}